

# 54<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes

Berlin, Germany, 1 – 5 October 2018

## Abstracts

### Index of Oral Presentations

- OP 01 Inflammatory events in type 2 diabetes
- OP 02 Foot prints
- OP 03 Unravelling nephropathy
- OP 04 The adipose tissue: from biology to intervention studies
- OP 05 Novel models for understanding complications
- OP 06 Beta cell connectivity and heterogeneity
- OP 07 New insights from clinical trials with incretin-based therapies
- OP 08 Diabetes gazing into the crystal ball
- OP 09 Pregnancy and gestational diabetes
- OP 10 Where, when and hows of rapid acting insulins
- OP 11 Pain is in the brain
- OP 12 Beta cell identity, degeneration and type 2 diabetes
- OP 13 GLP1 receptor agonists, SGLT2 inhibitors and the kidney: new lessons from large clinical trials
- OP 14 The bottom line: What's the best basal insulin?
- OP 15 Technological advances in the treatment of diabetes
- OP 16 Diabetes and mortality
- OP 17 Exercise: running back and forth from the gym to the culture dish
- OP 18 From stem cells to human pancreas development
- OP 19 SGLT2 inhibitors: new mechanisms and clinical evidence
- OP 20 Overriding mechanisms of NAFLD
- OP 21 Predicting complications
- OP 22 Sweetening the endothelium
- OP 23 How our brain impacts on diabetes
- OP 24 Beta cell signal transduction: new concepts
- OP 25 Hypoglycaemia: consequences and prevention
- OP 26 Diabetes: eat and heart beat
- OP 27 Liver at large
- OP 28 Novel drug therapies: moving beyond GLP1
- OP 29 Epigenetics: beyond the genes
- OP 30 Retinopathy: a different look at the eyes
- OP 31 Nephropathy: bedside and back to bench
- OP 32 Beta cells stick together to fight insulin resistance
- OP 33 Dietary patterns and metabolic regulation
- OP 34 Novelty in adipose tissue biology and lipid metabolism
- OP 35 Genetics of diabetes across the life course
- OP 36 Muscling up on diabetes
- OP 37 Adipose tissue: I have you under my skin
- OP 38 Novel actions of metformin and pioglitazone
- OP 39 Understanding diabetes through registry data
- OP 40 Innovation in genetics
- OP 41 Novel mechanisms of inflammation in obesity
- OP 42 Intercellular interactions and islet function
- OP 43 Do not let bugs pass by you
- OP 44 Clinical use of insulin: What works and what doesn't
- OP 45 Memory and mood
- OP 46 Neuropathy: nervy eyes

- OP 47 New insights in diabetes from mouse studies
- OP 48 Functional imaging of insulin secretion

### Index of Poster Sessions


- PS 001 Diabetes health burden
- PS 002 Diabetes prevalence
- PS 003 Type 2 diabetes prediction
- PS 004 Diabetes: therapeutic approaches
- PS 005 Prediction of type 1 diabetes
- PS 006 Diabetes progression
- PS 007 Diet and lifestyle influences
- PS 008 Diabetes complications
- PS 009 Epigenetics and gene regulation
- PS 010 Monogenic diabetes
- PS 011 Type 2 diabetes therapy intensification
- PS 012 Diabetes mortality
- PS 013 Diabetes across ethnicities
- PS 014 Genetics of diabetes
- PS 015 Environment and beta cell damage
- PS 016 Regulation of functional beta cell mass
- PS 017 Insulin secretion
- PS 018 Pathogenesis and treatment of type 1 diabetes
- PS 019 Beta cell signal transduction
- PS 020 Beta cell damage and protection
- PS 021 Clinical and experimental immunology in type 1 diabetes
- PS 022 Exercise is good for you
- PS 023 In gut we trust
- PS 024 Following the signal inside muscle or fat
- PS 025 Clocking in on exercise and nutrition
- PS 026 Healthy diet for a healthy rodent
- PS 027 Pinpointing pancreatic performance
- PS 028 Balancing the books: insulin delivery and clearance
- PS 029 Visit to the diabetes zoo: novel animal models
- PS 030 Keeping it in the family: glucagon, GIP, GLP1, GLP2
- PS 031 Slimming down: with or without surgery
- PS 032 Novel biomarkers
- PS 033 Inflammation, adipose tissue and obesity: human studies
- PS 034 Animal models of type 2 diabetes and obesity
- PS 035 Inflammation in type 2 diabetes: human studies
- PS 036 Inflammation in obesity and type 2 diabetes: mouse studies
- PS 037 Lipid metabolism in animal models
- PS 038 Weight regulation and obesity in humans
- PS 039 Obesity and lipid metabolism: studies in human-derived cells
- PS 040 Adipose tissue biology: animal studies
- PS 041 Lipid metabolism in humans and in cell models
- PS 042 Adipose tissue biology in humans
- PS 043 Weight regulation and obesity in humans and rodent models
- PS 044 Are SGLT2 inhibitors effective and safe in type 1 diabetes?
- PS 045 Microvascular effects of SGLT2 inhibitors: focus on kidneys and eyes
- PS 046 Efficacy and safety of the SGLT2 inhibitor ertugliflozin

glucose homeostasis. Here we attempted to explore a new molecular mechanism mediated by Clec11a (C-type lectin domain family 11, member A) in prevention of islets dysfunction during obesity.

**Materials and methods:** C57BL/6 mice aged 5 weeks fed a high-fat diet or standard diet for 14 weeks. Transcriptomic sequencing was performed with the islets of diet-induced obesity (DIO) C57BL/6 mice and normal food fed control mice. Differential gene transcription was confirmed by real-time PCR, and protein translation was verified by western blot and immunofluorescence. The proliferation of MIN6 cells was measured by CCK8. The insulin secretion was measured by ELISA.

**Results:** The body weight ( $49.29 \pm 0.79$  g vs.  $29.30 \pm 0.54$  g,  $P < 0.01$ , Fig 1.A), fasting blood glucose ( $7.58 \pm 0.58$  mmol/L vs.  $3.90 \pm 0.38$  mmol/L,  $P < 0.01$ , Fig 1.B), and insulin level in plasma ( $1240.95 \pm 92.30$  pg/mL vs.  $723.56 \pm 74.33$  pg/mL,  $P < 0.01$ , Fig 1.C) were higher in DIO mice than those of control mice. Moreover, the results of oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) exhibited the impaired glucose tolerance and insulin resistance in DIO mice ( $P < 0.05$ , Fig. 1D,E). The mRNA of Clec11a significantly decreased in islets of DIO mice in RNA-Seq experiment by 5 folds (Fig. 1F) and confirmed by real-time PCR (Fig. 1G). The expression heatmap of the top 100 changed genes is shown in Fig. 1H. As shown in Fig. 2, Clec11a staining is localized in islets. Palmitic acid (PA) treated cultured isolated islets expressed less Clec11a in a dose dependent manner (Fig. 3A,B). We then chose 0.5mM PA as the concentration in time course experiment. The protein expression of Clec11a demonstrated a waved trend with upregulated peak at 12 hours and then declined until a reversed level comparing to free fat acid (FFA-BSA) at 48h (Fig. 3C,D). The expression of Clec11a in MIN6 is also downregulated by PA in a dose dependent manner measured by real-time PCR (Fig. 4A) and western blot (Fig. 4B,C). Additionally, PA treatment inhibited the proliferation (Fig. 5A) and the secretion of insulin (Fig. 5B) in MIN6. The treatment of Clec11a protein containing medium rescued the proliferation ( $0.66 \pm 0.05$  vs.  $0.42 \pm 0.04$ ,  $P < 0.01$ , Fig. 5C), the secretion of insulin in high glucose ( $22708.16 \pm 2275.08$  pg/mg/h vs.  $11911.69 \pm 1421.1$  pg/mg/h,  $P < 0.01$ , Fig. 5D). Moreover, the phosphorylation level of Akt was elevated by Clec11a protein containing medium in PA treated MIN6 cells by 2 folds ( $P < 0.05$ , Fig. 5E).

**Conclusion:** Clec11a might protects the islets function injured by lipotoxicity via a mechanism of regulating pancreatic beta cell proliferation and secretion.



**Disclosure:** R. Shi: None.

## PS 017 Insulin secretion

### 391

#### Evidence for differential role of beta-arrestin2 in GLP-1 and GIP signalling in mouse pancreatic beta cells

M.A. Ravier<sup>1</sup>, J. Obeid<sup>1</sup>, M. Leduc<sup>1</sup>, S. Costes<sup>1</sup>, P. Gilon<sup>2</sup>, S. Dalle<sup>1</sup>, G. Bertrand<sup>1</sup>;

<sup>1</sup>Institut de Genomique Fonctionnelle, Montpellier, France, <sup>2</sup>Université Catholique de Louvain, Brussels, Belgium.

**Background and aims:** The scaffold protein beta-arrestin2 (ARRB2) is known to uncouple G protein coupled receptors (GPCR) from G protein and to recruit new signaling pathways (such as ERK1/2) to the activated GPCR. Several groups have reported a direct interaction of the GLP-1 receptor (GLP-1R) but not of the GIP receptor (GIPR) with ARRB2 in non beta cells. Nevertheless, we and others failed to detect any differences for insulin secretion in response to 20–100 nM GLP-1 from *Arb2*<sup>-/-</sup> mouse pancreatic islets. Our aim was to determine if ARRB2 could be involved in GLP-1R and GIPR signaling in mouse beta cells.

**Materials and methods:** The experiments were carried out in beta cells from four-month-old *Arb2*<sup>+/+</sup> and *Arb2*<sup>-/-</sup> male mice. cAMP production (CAMP-S-epac), endogenous PKA (AKAR3) and ERK1/2 (EKAR) activations were measured after adenoviral infection of cells with FRET-based sensors of interest by live microscopy. ERK1/2 phosphorylation was also determined by immunofluorescence.

**Results:** Compared to *Arb2*<sup>+/+</sup> mice, *Arb2*<sup>-/-</sup> mice displayed a better oral glucose tolerance despite an impaired i.p. glucose tolerance and a decrease in beta cell mass. This was associated with a significant increase in plasma insulin concentration after the oral glucose administration ( $p < 0.05$ ), suggesting a greater incretin effect in *Arb2*<sup>-/-</sup> mice. Insulin secretion was then measured from isolated islets in response to both incretin hormones: GIP and GLP-1. Unexpectedly, whereas insulin secretion from *Arb2*<sup>-/-</sup> isolated islets was significantly reduced in response to GIP (100 pM,  $p < 0.05$ ), insulin secretion was larger with physiological concentrations of GLP-1 (1 and 10 pM GLP-1;  $p < 0.05$ ). By contrast, supra-physiological concentrations of GLP-1 (1 nM–10 nM) induced similar insulin secretion in *Arb2*<sup>+/+</sup> and *Arb2*<sup>-/-</sup> islets. The larger insulin release with physiological concentrations of GLP-1 was associated with an increased cAMP production and PKA activation in *Arb2*<sup>-/-</sup> beta cells, while cytosolic [Ca<sup>2+</sup>]<sub>i</sub> increases and emptying of the endoplasmic reticulum were both similarly affected in *Arb2*<sup>+/+</sup> and *Arb2*<sup>-/-</sup> beta cells. Conversely, GLP-1-induced activation of ERK1/2 was strongly decreased (~50%,  $p < 0.05$ ) in *Arb2*<sup>-/-</sup> beta cells, but the re-expression of ARRB2 in *Arb2*<sup>-/-</sup> beta cells, using an adenovirus encoding ARRB2-GFP, completely restored ERK1/2 phosphorylation induced by GLP-1 ( $p < 0.01$ ).

**Conclusion:** Our study revealed in living mouse beta cells, a differential role of ARRB2 in GLP-1R and GIPR signalling. For GLP-1R, ARRB2 contributes to a partial uncoupling for the production of cAMP, the activation of PKA and consequently insulin secretion in the pM range of GLP-1, which is the physiological circulating concentration of the incretin. On the other hand, ARRB2 is required for GLP-1-induced full activation of ERK1/2. For GIPR, ARRB2 is required for GIP-induced amplification of insulin secretion. Therefore, any variation in the expression of ARRB2, as observed in diabetic states, should affect differentially the signaling of GLP-1R and GIPR.

**Disclosure:** M.A. Ravier: None.

### 392

#### CB1 and CB2 antagonists stimulate insulin secretion and regulate human and mouse islet viability

I. Ruz-Maldonado<sup>1</sup>, B. Liu<sup>1</sup>, P. Atanes<sup>1</sup>, A. Pingitore<sup>1</sup>, G.C. Huang<sup>1</sup>, D. Baker<sup>2</sup>, S.J. Persaud<sup>1</sup>;